Salute e Benessere

Press Release: Sanofi's Board of Directors proposes the appointment of Clotilde…

Sanofi's Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors Paris, February 22, 2024. At its meeting on February 22, 2024, Sanofi's Board of Directors has decided to propose, on the occasion of its next General Shareholder Meeting to be held on April 30, 2024, the renewal of the terms of office of Rachel Duan and Lise Kingo and the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent...
Nasdaq GlobeNewswire
22/02/2024

Microbiome Diagnostics Market Worth $300 million | MarketsandMarkets™.

Browse in-depth TOC on "Microbiome Diagnostics Market" Browse in-depth TOC on "Microbiome Diagnostics Market" 152 - Tables 38 - Figures 185 - Pages Microbiome Diagnostics Market Scope: The kits & reagents accounted for the largest share of the microbiome diagnostics market, by product segment, in 2022. The global microbiome diagnostics market is segmented into instruments and reagents & kits based on product. High consumption of consumables such as kits...
PR Newswire
22/02/2024

Psychedelics set to be the revolutionary treatments in pscyhiatry - Thelansis…

The next psychedelic that could reach the U.S. market is COMP360 psilocybin therapy (by COMPASS Pathways) for treatment-resistant depression (TRD), which comprises nearly one-third of patients with major depressive disorder (MDD).2 The therapy is in Phase 3 of clinical development and could receive USFDA approval by 2026. Notably, the therapy targets some key clinical unmet needs in TRD patients, for example, a rapid onset of action, less-frequent dosing, durability of response.4 Because of…
PR Newswire
22/02/2024

NeoChord, Inc. Appoints New Chief Executive Officer to Lead Commercialization…

"One of the most significant clinical gaps in structural heart innovation is providing patients a treatment option to address mitral regurgitation before the disease progresses to stages where the heart becomes damaged. The opportunity to develop a first-line therapy for mitral valve disease, by resolving regurgitation early in the disease state, is incredibly compelling," said Berg. "One of the most significant clinical gaps in structural heart innovation is providing patients a…
PR Newswire
22/02/2024

AtomVie Global Radiopharma Collaborates with RLS & UPPI to Strengthen its…

"Our commitment to transforming patient lives through high-quality radiopharmaceuticals is at the core of this partnership with RLS and UPPI," commented Bruno Paquin, CEO of AtomVie. He added "These collaborations strengthen our ability to deliver critical radiopharmaceuticals to more locations, ensuring timely access for patients who rely on the products. These partnerships not only meet the current demand but position us for future growth, as we meaningfully expand our…
PR Newswire
22/02/2024

Notice of Nexstim Plc's 2023 Full Year Results

Press release,Helsinki,22 February2024 at 3 PM(EET) Noticeof NexstimPlc's 2023 Full Year Results Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") will announce its full year results for the year ended 31 December 2023 on Tuesday 27 February 2024 at 9.00 am Finnish time.The company will hold two live webinars for media, investors, and analysts on Tuesday 27 February 2024. CEO Mikko Karvinen and CFO Joonas Juokslahti will present the financial and operational results...
Nasdaq GlobeNewswire
22/02/2024

Kakao Brain Debuts 'KARA-CXR', a Web-Based Radiology Report Service Powered by…

Through this user-friendly and seamless solution, medical researchers can experience various functions such as: receiving two types of AI interpretations of chest X-ray images together (a simple report and a detailed full report); ability to upload multiple DICOM files at once and receiving multiple reports simultaneously; and being able to share the AI interpretations within the research group or medical community. It also features compliant security measures that anonymize and protect any…
PR Newswire
22/02/2024

Curasight publishes information memorandum in connection with forthcoming rights…

Information Memorandum Information Memorandum Full terms and conditions for the Rights Issue as well as other information about the Company and further information about subscription commitments, is included in the Information Memorandum. The Information Memorandum is available on the Company's, Nordic Issuing AB's and Redeye AB's respective websites ( www.curasight.com, www.nordic-issuing.se,www.redeye.se ). Subscription forms will be available on the Company's, Nordic Issuing AB's,...
PR Newswire
22/02/2024

AC Immune Announces Upcoming Presentations at AD/PD™ 2024

AC Immune Announces Upcoming Presentations at AD/PD™ 2024Multiple presentations at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2024)Andrea Pfeifer, Ph.D., CEO to lead AC Immune-sponsored symposium on alpha-synuclein pathologiesLausanne, Switzerland, February 22, 2024– AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upcoming presentations...
Nasdaq GlobeNewswire
22/02/2024

Curium Announces Submission of the Marketing Authorization Application for…

®(INN: Piflufolastat ( 18 F) formerly known as ( 18 F)-DCFPyL) submitted by exclusive Swiss distributor b.e.imaging AG on 31 January 2024 to the Swiss Agency for Therapeutic Products (Swissmedic) has been accepted for evaluation.PYLCLARI ®is indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in adults with prostate cancer (PCa) in the following clinical settings: Primary staging of patients with high-risk...
Nasdaq GlobeNewswire
22/02/2024

Innovative Hyperpigmentation Solutions: Insights from Our Latest Research

About the Study: About the Study : The research titled "Cysteamine Isobionic-Amide Complex Versus Kligman's Formula for the Treatment of Melasma: Equal Efficacy and Rapid Onset of Action" explores the effectiveness of a new Cysteamine Isobionic-Amide complex in comparison to the Modified Kligman's Formula (mKF), a longstanding cornerstone in melasma treatment. Despite mKF's efficacy, its prolonged use raises concerns due to potential side effects, highlighting the need for…
PR Newswire
22/02/2024

Telix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth…

Progress across the core pipeline includes: Progress across the core pipeline includes: DrChristian Behrenbruch, Managing Director and Group CEO commented: "This is an excellent result which demonstrates the strength of the Telix business model. We have achieved profitability while intensively investing in the development of our late-stage assets and the scale-up of our commercial infrastructure and marketing activity. This has resulted in Telix capturing a meaningful market share in...
PR Newswire
22/02/2024

Orion and Save the Children Finland announce cooperation to promote well-being…

ORION CORPORATIONPRESS RELEASE22 FEBRUARY 2024 at 11.00 EET Orion and Save the Children Finland announce cooperation to promote well-being of children in Finland and globally Orion Corporation and Save the Children Finland have signed a cooperation agreement for the year 2024. With Orion's donation of EUR 50,000, Save the Children Finland will promote the well-being of underprivileged children and young people in Finland and the availability of vital health and...
Nasdaq GlobeNewswire
22/02/2024

Kling Biotherapeutics to Present Discoveries on its Primary B-Cell Screening…

Lead program KBA1412 is advancing in a Phase 1 clinical study, targeting advanced solid malignant tumors Lead program KBA1412 is advancing in a Phase 1 clinical study, targeting advanced solid malignant tumors AMSTERDAM,Feb. 22, 2024/PRNewswire/ -- Kling Biotherapeutics ("Kling" or "the Company"), a clinical stage biotech company developing antibody-based drugs against targets identified from its primary B-cell screening platform, today announces that it will be presenting…
PR Newswire
22/02/2024

STORM Therapeutics to Present Findings on its First-in-Class METTL1 tRNA…

Data demonstrated that: Data demonstrated that: Oliver Rausch, Chief Scientific Officer at STORM Therapeutics, said: "We are delighted to present this exciting new work which demonstrates that targeting specific tRNA pathways via inhibition of the novel RNA methyltransferase METTL1 results in cancer cell reprogramming and profound cancer growth inhibitionin vivo. This follows hot on the heels of our groundbreaking work on METTL3 leading to the discovery of STC-15, currently in...
PR Newswire
22/02/2024

Novo Nordisk Foundation: Researchers aim to advance quantum sensing to transform…

The advancement of the quantum sensing technology enables us to register and measure small changes in motion and electric and magnetic fields far better than classical sensors. These new quantum-based capabilities will enable the sensing of faint signals buried deep within the body, such as weak electromagnetic impulses from nerves, the heart or the brain. This provides important information that can facilitate earlier detection and prevention of diseases. The advancement of the quantum…
PR Newswire
22/02/2024

Photocure Partner Asieris to present First-ever Results of the international…

Read Asieris' full media release here: https://asieris.com/asieris-to-unveil-first-ever-results-of-the-international-multicenter-phase-iii-clinical-study-for-1702-a-non-surgical-treatment-for-cervical-hsil-at-the-2024-eurogin/ Read Asieris' full media release here:https://asieris.com/asieris-to-unveil-first-ever-results-of-the-international-multicenter-phase-iii-clinical-study-for-1702-a-non-surgical-treatment-for-cervical-hsil-at-the-2024-eurogin/ Cevira is a breakthrough photodynamic...
PR Newswire
22/02/2024

Indivior Announces Q4 / FY 2023 Financial Results

Webcast link: https://edge.media-server.com/mmc/p/kymnerij Participants may access the presentation telephonically by registering with the following link: https://register.vevent.com/register/BI7bc18cb84a3744af8c4ad20973d37a5a Webcast link:https://edge.media-server.com/mmc/p/kymnerij Participants may access the presentation telephonically by registering with the following link:https://register.vevent.com/register/BI7bc18cb84a3744af8c4ad20973d37a5a (Please note this is a change from...
PR Newswire
22/02/2024

Annual Financial Statements Update for the Year Ended October 31, 2023

Out of an abundance of caution in the event that the Company is unable to make the Required Filings on or before the Filing Deadline, the Company has applied to the Ontario Securities Commission (the "OSC") pursuant to Part 3 of National Policy 12-203 203 – Management Cease Trade Orders ("NP 12-203") for a management cease trade order ("MCTO") that will prohibit the management of the Company from trading in the securities of the Company until such time as the…
PR Newswire
21/02/2024

BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY…

With the transaction now complete, BioVaxys is working on integrating the acquired assets into the Company. BioVaxys President and Chief Operating Officer Kenneth Kovan stated "We now have massive opportunities in oncology, infectious disease, allergy desensitization, and autoimmune diseases. Adding several clinical-stage programs was critical for us becoming a product-centric company, but there are always inherent risks with clinical programs, and they require significant investment…
PR Newswire
21/02/2024

Organ-on-Chip Market Worth $631,073 thousand | MarketsandMarkets™.

Browse in-depth TOC on "Organ-on-Chip Market"396 - Tables38 - Figures352 - Pages Browse in-depth TOC on "Organ-on- Chip Market "396 - Tables 38 - Figures 352 - Pages Organ-on- Chip MarketScope: Disease-based model subsegment is the fastest-growing of the organ-on-chip market by model type Among the model type subsegments, the market is segmented organ-based model and disease-based models. In 2023, the disease-based model segment accounted for the highest growth...
PR Newswire
21/02/2024

Notice for the Annual General Meeting of Novo Nordisk A/S

Bagsværd, Denmark, 21 February 2024– The Annual General Meeting of Novo Nordisk A/S will be held on:Thursday 21 March 2024 at 14.00 (CET) The Annual General Meeting is held as a partially electronic general meeting. Accordingly, shareholders can choose between participating in person at Bella Center, Center Boulevard 5, DK-2300 Copenhagen S, Denmark or participating virtually via an IT application. We encourage shareholders to exercise their rights by submitting proxies or votes by...
Nasdaq GlobeNewswire
21/02/2024

Jazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer

Mr. Johnson joins Jazz Pharmaceuticals with over 35 years of financial experience, most recently leading Eli Lilly and Company's treasury and investor relations operations as Group Vice President of Finance. In his new role, Mr. Johnson will oversee financial reporting, accounting, tax, treasury, risk management, financial planning and analysis, information services and facilities. He will also oversee the Company's investor relations and corporate development functions. Mr. Johnson joins…
PR Newswire
21/02/2024

Lutris Pharma Announces Publication of Positive Data From Its Phase 1/2 Trial of…

Part 2 Data Showed Clinically Relevant Treatment Advantage of Approximately 30% in Patients on LUT014 Versus Placebo Part 2 Data Showed Clinically Relevant Treatment Advantage of Approximately 30% in Patients on LUT014 Versus Placebo TEL AVIV, Israel,Feb. 21, 2024/PRNewswire/ -- Lutris Pharma,a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced the publication of data from its phase 1/2...
PR Newswire
21/02/2024
Altri  Comunicati